Highlights from: the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA; January 15-17, 2009.
Quill
Timothy
T
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000068818:Cetuximab; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery; D005819:Genetic Markers; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D020360:Neoadjuvant Therapy; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005819:Genetic Markers; D000077544:Panitumumab; D000068818:Cetuximab